Last reviewed · How we verify
Ilaprazole Enteric-Coated Tablets
Ilaprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.
Ilaprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Gastric ulcer, Duodenal ulcer, Gastroesophageal reflux disease (GERD).
At a glance
| Generic name | Ilaprazole Enteric-Coated Tablets |
|---|---|
| Sponsor | The Third Xiangya Hospital of Central South University |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Ilaprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This reduces intragastric acidity and allows healing of acid-related lesions. It is a benzimidazole-based PPI with a mechanism similar to omeprazole and lansoprazole.
Approved indications
- Gastric ulcer
- Duodenal ulcer
- Gastroesophageal reflux disease (GERD)
- Acid-related gastrointestinal disorders
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
- Dizziness
Key clinical trials
- The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers (PHASE4)
- Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection (PHASE4)
- Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |